Biotech: Page 34
-
PharmaVoice Team/PharmaVoice
Postapproval Studies: More Critical and Challenging Than Ever
By Robin Robinson Phase IV data are in high demand by more stakeholders. As the need for postapproval data reaches a critical point, the industry explores the multiple options and struggles to determine which methods are best for collecting and analyzing important data. There are as many ways to ...
By PharmaVoice Team • May 29, 2012 -
PharmaVoice Team/PharmaVoice
Insights from the C-Suite: Biotechnology Companies
C-Suite Biotech Companies Insights from the C-Suite: Biotechnology Companies Biotech executives address the need for regulations that address the specific needs of biotech and how funding challenges can impact innovation. According to a recent report by US Biotech Market Analysis, the United Stat...
By Taren Grom • April 27, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Addressing Reimbursement During Development
Denise Myshko Pharma companies are experiencing greater scrutiny from government, private payers, and consumers. Creating a comprehensive reimbursement plan that begins at early phases of product development is essential in successfully obtaining coverage. Increasingly in the United States and in...
By Denise Myshko • April 27, 2012 -
PharmaVoice Team/PharmaVoice
New Course for Biotherapeutics
Denise Myshko Companies developing biotherapeutics are beginning to study indications beyond cancer and autoimmune and infectious diseases and are researching how antibodies and proteins can be used to treat other conditions, such as pain and cardiovascular conditions, that have traditionally bee...
By Denise Myshko • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Word Building Strong Partnerships John Gargiulo, President and CEO of Daiichi Sankyo Inc., talks about how a philanthropic gift 100 years ago led to a global collaboration for drug development. PV: What is Daiichi Sankyo’s connection to Washington, D.C.’s cherry trees? Gargiulo: One hundred year...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Talent Pool executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Dr. Charlotte KREMER Astellas Names Global Medical Affairs Head Charlotte Kremer, M.D., has joined Astellas Pharma as head of the global medical affairs organization. Dr. Kremer wa...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
Tools of the Trade New electronic and web-based applications, sites, and technologies By Carolyn Gretton New Tool from HealthSTAR Provides Virtual Bridge Between KOLs, HCPs Trend: New advances in digital platforms are allowing for the capture of peer-to-peer programs via a digital platform that ...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
What's New
What’s New New healthcare-related products, services, and companies By Carolyn Gretton CAHG Joins Forces With TBWAWorldHealth Trend: Alliances among global communications companies aim to help healthcare clients in major and pharmerging markets to create a healthier world. CAHG, a healthcare comm...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Competitive Intelligence and Strategy in Today's Environment
s the industry experiences a myriad of new pressures, many of its tried-and-true business practices are shifting to meet new challenges, and the world of competitive intelligence (CI) is no exception. Some in the industry are predicting that not only will CI soon be defined differently, but its r...
By Robin Robinson • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Pharma 3.0
As the industry evolves to address a new ecosystem within the complex and global drug development and commercialization arena, companies will need to be open to using new technologies, thinking, and processes to make healthcare more sustainable, affordable, and accessible; improve the efficiency ...
By PharmaVoice Team • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Final Phase Goal: Maximize Uptake While Speeding to Launch
In every phase of drug development today, processes are more complex and more costly than ever and the drive to reduce time and expenditure is more critical. In today’s ever-changing marketplace, this holds true especially for the last stages of the process: registration, launch, and postlaunch. ...
By PharmaVoice Team • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
New Models for Early Development
The number of drugs entering Phase I fell 47% and the number of drugs entering Phase II trials fell 53%, according to 2011 Pharmaceutical R&D Factbook complied by CMR International. Industry experts say there is a trend toward conducting fewer, more complex early-phase studies that often incl...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Achieving Value from Discovery and Preclinical Endeavors
The need to increase value and productivity throughout the development process has never been more critical. R&D expenditure continued to drop in 2010 to an estimated three-year low of $68 billion, and drug success rates continue to show the declining trends of the past decade, according to t...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Molecule to Market - Along the Continuum
According to the most recent report from Tufts Center for the Study of Drug Development, it still takes about 10 to 15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. Only one ...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Moving Dermatology Forward William Griffing, President and General Manager at Bayer HealthCare’s Dermatology Unit, discusses the shifting business model in the dermatology specialty segment. PV: How does changing the company’s name from Intendis Inc. to Bayer HealthCare (BHC) shift the company’...
By William Griffing • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Anders EKBLOM Dr. Briggs MORRISON AstraZeneca Bolsters R&D Leadership Global pharmaceutical company AstraZeneca has tapped Anders Ekblom, M.D., to build and lead the science and technology integration office within the company’s R&D organization. In addition to th...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: Kantar Health Focuses on Cancer Patients’ Healthcare Decision-Making Aerpio Therapeutics Makes Debut In other news… Inspiration Biopharmaceuticals Moves Corporate Headquarters AROUND THE GLOBE Kantar Health, a healthcare-fo...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
What's Ahead for Biosimilars
Denise Myshko Uncertainty lies ahead for the biosimilar market, as manufacturers await FDA guidance. Biosimilars could represent a multi-billion dollar market in the United States, although some questions remain, including the uptake by physicians and payers, pricing of biosimilars, and how the F...
By Denise Myshko • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Digital Patient-Centric Communications: Listen and Learn
Learning to listen and listening to learn are critical to a successful social networking marketing plan. While the buzzword in marketing these days is patient-centric, the industry still struggles with shifting its focus from products to consumers. Years of pushing product messaging out into the ...
By PharmaVoice Team • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Creating Jobs in the Industry Safi Bahcall, Ph.D., CEO, Synta Pharmaceuticals, discusses how the extension of the R&D tax credit for life-sciences companies can accelerate job creation. PV: What do you think employment within the industry will look like in 2012? Bahcall: As the U.S. economy...
By Safi Bahcall • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Aaron BERG Essentialis Names CEO Essentialis, a pharmaceutical company focused on a novel medicine for the treatment of cardiovascular and metabolic disease, has promoted Aaron Berg to CEO, fro...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
New electronic and web-based applications, sites, and technologies By Carolyn Gretton New Tool from HRM Aims to Improve Medication Adherence, Patient Outcomes Trend: A growing number of healthcare providers are using intuitive technological tools to connect directly with patients to provide info...
By Carolyn Gretton • Jan. 26, 2012 -
PharmaVoice Team/PharmaVoice
Making a Difference
Taren Grom Dr. Brad Thompson, Executive Chairman, CEO, and President of Oncolytics Biotech Inc., is excited about the opportunities that his company and the biotech field in general can have to make transformative changes in the standard of care for patients. Dr. Brad Thompson has a personal con...
By Robin Robinson • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Forecasting Pharma's Future
Forecasting Pharma’s Future Denise Myshko Given the volatility of today’s financial landscape, companies, more than ever, need a robust forecasting strategy that is clear, effective, and accurate. As companies seek to negotiate the volatility of emerging markets, the uncertainties of healthcare ...
By Denise Myshko • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Multichannel Measurement: It's Not All About ROI
Robin Robinson Measuring the effectiveness of every channel now available — from traditional to nontraditional, online and off — is at best difficult, especially as advances in technology and social media networks continually create new ways to reach the consumer, and, at worst, impossible when i...
By PharmaVoice Team • Dec. 22, 2011
Previous
